These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3507246)

  • 1. Induction of malignant transformation in vitro and mammary tumors in rats by two new potent anthracycline antitumor antibiotics, morpholinodaunomycin and cyanomorpholinoadriamycin.
    Westendorf J; Mohr U; Marquardt H
    Cell Biol Toxicol; 1987 Mar; 3(1):17-21. PubMed ID: 3507246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship of anthracycline-induced genotoxicity in vitro.
    Westendorf J; Marquardt H; Marquardt H
    Cancer Res; 1984 Dec; 44(12 Pt 1):5599-604. PubMed ID: 6388827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumor antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin.
    Westendorf J; Groth G; Steinheider G; Marquardt H
    Cell Biol Toxicol; 1985 Jan; 1(2):87-101. PubMed ID: 3917129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests.
    Westendorf J; Marquardt H; Ketkar MB; Mohr U; Marquardt H
    Cancer Res; 1983 Nov; 43(11):5248-51. PubMed ID: 6352017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin.
    Marquardt H; Philips FS; Sternberg SS
    Cancer Res; 1976 Jun; 36(6):2065-9. PubMed ID: 1268859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells.
    Babudri N; Pani B; Tamaro M; Monti-Bragadin C; Zunino F
    Br J Cancer; 1984 Jul; 50(1):91-6. PubMed ID: 6378238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of oxygen uptake in vitro as an index of cardiac toxicity induced by new anthracyclines.
    Cini-Neri G; Neri B
    Anticancer Res; 1986; 6(2):195-7. PubMed ID: 3458425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.
    Zbinden G; Brändle E
    Cancer Chemother Rep; 1975; 59(4):707-15. PubMed ID: 1175165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity.
    Andrivon W; Callais F; Nafziger J; Monneret C; Guillosson JJ
    Mutat Res; 1995 Oct; 344(3-4):135-40. PubMed ID: 7491131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genotoxic and mutagenic activity of antineoplastic anthracyclines and their aglycones: study in two test-systems].
    Vasil'eva SV; Makhova EV; Efremenkova OV; Bartoshevich IuE
    Genetika; 1996 Feb; 32(2):233-9. PubMed ID: 8713623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects.
    Singh Y; Ulrich L; Katz D; Bowen P; Krishna G
    Toxicol Appl Pharmacol; 1989 Aug; 100(1):9-23. PubMed ID: 2763305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the structure of new anthracycline antibiotics on their biological properties.
    Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
    Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?
    Durand RE
    Cancer Chemother Pharmacol; 1990; 26(3):198-204. PubMed ID: 2357767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammary tumors induced in rats by adriamycin and daunomycin.
    Solcia E; Ballerini L; Bellini O; Sala L; Bertazzoli C
    Cancer Res; 1978 May; 38(5):1444-6. PubMed ID: 639071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
    Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation].
    Shinozawa S; Gomita Y; Araki Y
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):805-9. PubMed ID: 1605657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin enhances the genotoxicity of doxorubicin in Chinese hamster V79 cells via noncovalent DNA binding.
    Snyder RD
    Drug Chem Toxicol; 2009; 32(1):17-20. PubMed ID: 19514934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
    Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
    J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.